Zalicus begins new human trial of reformulated pain drug

Zalicus Inc. ($ZLCS) is proceeding with a Phase I clinical trial of a new pain drug designed to use "multiple state-of-the-art" drug delivery techniques so it is more soluble and present in the body than in a previous version. The Cambridge, MA, company formally known as CombinatoRx said an earlier version of the novel oral N-type calcium channel blocker was tested in more than 200 patients. While that version may have been less soluble, the drug was well tolerated, Zalicus said. The new study will assess the drug's activity and safety through the end of 2011 and into early 2012. If all goes well, a Phase II trial for the drug will commence soon after, Zalicus President and CEO Mark Corrigan said in a statement. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.